CIK 0001590560
- Large accelerated filer
uniQure N.V.
Sign in to watch- Ticker
- QURE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +1 339-970-7000
- Business address
- PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP
- Former names
- uniQure B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $192,950
- in 1 filing, $193K under 10b5-1 plans
Net −$192,950. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Potts Jeannette Chief Legal Officer | Sale | −8,578 | $9.95 | $85K | 106,495 |
| 2026-03-02 | Abi-Saab Walid Chief Medical Officer | Sale | −1,660 | $9.95 | $17K | 148,777 |
| 2026-02-25 | Kapusta Matthew C CEO, Managing Director | Sale | −12,378 | $23.86 | $295K | 639,076 |
| 2026-02-25 | KLEMT CHRISTIAN Chief Financial Officer | Sale | −6,217 | $23.86 | $148K | 211,513 |
| 2026-01-12 | Gut Robert Director | Exercise or conversion 10b5-1 | +17,810 | $14.08 | $251K | 57,955 |
| 2026-01-12 | Gut Robert Director | Sale 10b5-1 | −17,310 | $24.39 | $422K | 40,645 |
| 2026-01-12 | Gut Robert Director | Sale 10b5-1 | −500 | $25.03 | $13K | 40,145 |
| 2026-01-12 | Gut Robert Director | Sale 10b5-1 | −7,803 | $25.09 | $196K | 32,342 |
| 2026-01-12 | Gut Robert Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −17,810 | 0 | ||
| 2026-01-09 | Kaye Jack Director | Exercise or conversion 10b5-1 | +6,390 | $19.39 | $124K | 26,829 |
| 2026-01-09 | Kaye Jack Director | Sale 10b5-1 | −6,390 | $27.28 | $174K | 20,439 |
| 2026-01-09 | Kaye Jack Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −6,390 | 0 | ||
| 2025-11-06 | Gut Robert Director | Exercise or conversion 10b5-1 | +15,840 | $4.57 | $72K | 71,579 |
| 2025-11-06 | Gut Robert Director | Sale 10b5-1 | −15,840 | $27.22 | $431K | 55,739 |
| 2025-11-06 | Gut Robert Director | Sale 10b5-1 | −15,594 | $27.30 | $426K | 40,145 |
| 2025-11-06 | Gut Robert Director | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −15,840 | 0 | ||
| 2025-11-04 | Kaye Jack Director | Exercise or conversion 10b5-1 | +10,000 | $7.37 | $74K | 30,439 |
| 2025-11-04 | Kaye Jack Director | Sale 10b5-1 | −10,000 | $30.36 | $304K | 20,439 |
| 2025-11-04 | Kaye Jack Director | Exercise or conversion 10b5-1 | +11,000 | $5.37 | $59K | 31,439 |
| 2025-11-04 | Kaye Jack Director | Sale 10b5-1 | −11,000 | $30.34 | $334K | 20,439 |
Page 6 of 13 · 251 trades